Prescribers should be aware of a dose-proportional increase in cannabidiol exposure for doses between 5 and 20 mg/kg when cannabidiol is administered following a high-fat meal.

This new formulation of cannabidiol was generally safe and well tolerated, with the most commonly reported adverse events being headache (17%) and diarrhoea (8%). The formulation is now available in the public domain.

Safety and pharmacokinetic data obtained following a high-fat meal were consistent with data from other studies of purified pharmaceutical-grade cannabidiol, strengthening support for the idea of administering CBD with food to maximize bioavailability.

There is potential for a substantial variation in cannabidiol bioavailability between doses if the fat content of the associated meal varies significantly.